Compounders Research Compare

PolyPid Ltd.(PYPD)

Biotechnology · Petah Tikva, HM

$5.11-0.09 (-1.73%)

Delayed quote: Oct 6, 2026, 3:39 PM EDT

About PolyPid Ltd.

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

Petah Tikva, HM

72 employees

www.polypid.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dikla Czaczkes Akselbrad

View full financials

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T19:43:02.643Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:43:02.643Z.

Quote observation: 2026-10-06T19:39:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 97,515,152
Total debt · period ending 2026-06-30: 1,572,000
Cash · period ending 2026-06-30: 6,563,000
TTM revenue · period ending 2026-06-30: 0

FMP input reference: d00a9c235f8f3f2200d332a4911885706ef223ec632fccfa45bb3326c1a5dd06

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PYPD EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

PYPD Competitors' EV/Sales Ratio

PolyPid Ltd.

Current

Market Cap

$97.52M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Korro Bio, Inc.

Market Cap

$97.49M

EV/Sales Ratio

48.20x

TTM Avg

38.61x

3Y Avg

38.86x

5Y Avg

28.17x

OnKure Therapeutics, Inc.

Market Cap

$98.00M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Park Dental Partners, Inc. Common Stock

Market Cap

$96.58M

EV/Sales Ratio

N/A

TTM Avg

0.49x

3Y Avg

0.49x

5Y Avg

0.49x

Conexeu Sciences Inc.

Market Cap

$96.46M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Milestone Pharmaceuticals Inc.

Market Cap

$94.81M

EV/Sales Ratio

28.56x

TTM Avg

95.40x

3Y Avg

61.44x

5Y Avg

43.17x

The Joint Corp.

Market Cap

$101.22M

EV/Sales Ratio

1.39x

TTM Avg

27.18x

3Y Avg

11.41x

5Y Avg

8.91x

Anixa Biosciences, Inc.

Market Cap

$102.92M

EV/Sales Ratio

N/A

TTM Avg

501.64x

3Y Avg

356.48x

5Y Avg

292.72x

Polaryx Therapeutics, Inc. Common Stock

Market Cap

$104.18M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Equillium, Inc.

Market Cap

$90.73M

EV/Sales Ratio

N/A

TTM Avg

3.31x

3Y Avg

1.36x

5Y Avg

1.36x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
PolyPid Ltd. (PYPD)	$97.52M	N/A	N/A	N/A	N/A
Korro Bio, Inc. (KRRO)vs ›	$97.49M	48.20x	38.61x	38.86x	28.17x
OnKure Therapeutics, Inc. (OKUR)vs ›	$98.00M	N/A	N/A	N/A	N/A
Park Dental Partners, Inc. Common Stock (PARK)vs ›	$96.58M	N/A	0.49x	0.49x	0.49x
Conexeu Sciences Inc. (CNXU)vs ›	$96.46M	N/A	N/A	N/A	N/A
Milestone Pharmaceuticals Inc. (MIST)vs ›	$94.81M	28.56x	95.40x	61.44x	43.17x
The Joint Corp. (JYNT)vs ›	$101.22M	1.39x	27.18x	11.41x	8.91x
Anixa Biosciences, Inc. (ANIX)vs ›	$102.92M	N/A	501.64x	356.48x	292.72x
Polaryx Therapeutics, Inc. Common Stock (PLYX)vs ›	$104.18M	N/A	N/A	N/A	N/A
Equillium, Inc. (EQ)vs ›	$90.73M	N/A	3.31x	1.36x	1.36x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics